收费全文 | 75323篇 |
免费 | 6094篇 |
国内免费 | 2524篇 |
耳鼻咽喉 | 409篇 |
儿科学 | 2056篇 |
妇产科学 | 808篇 |
基础医学 | 10953篇 |
口腔科学 | 867篇 |
临床医学 | 5973篇 |
内科学 | 12010篇 |
皮肤病学 | 1351篇 |
神经病学 | 5038篇 |
特种医学 | 1062篇 |
外国民族医学 | 11篇 |
外科学 | 6808篇 |
综合类 | 9919篇 |
现状与发展 | 14篇 |
预防医学 | 5308篇 |
眼科学 | 1066篇 |
药学 | 11878篇 |
21篇 | |
中国医学 | 4682篇 |
肿瘤学 | 3707篇 |
2023年 | 1028篇 |
2022年 | 1276篇 |
2021年 | 2347篇 |
2020年 | 2342篇 |
2019年 | 2842篇 |
2018年 | 2835篇 |
2017年 | 2525篇 |
2016年 | 2502篇 |
2015年 | 2773篇 |
2014年 | 4458篇 |
2013年 | 5241篇 |
2012年 | 4563篇 |
2011年 | 5248篇 |
2010年 | 4252篇 |
2009年 | 3587篇 |
2008年 | 3453篇 |
2007年 | 3289篇 |
2006年 | 2845篇 |
2005年 | 2557篇 |
2004年 | 2177篇 |
2003年 | 1942篇 |
2002年 | 1595篇 |
2001年 | 1409篇 |
2000年 | 1074篇 |
1999年 | 1029篇 |
1998年 | 794篇 |
1997年 | 752篇 |
1996年 | 657篇 |
1995年 | 662篇 |
1994年 | 584篇 |
1993年 | 551篇 |
1992年 | 502篇 |
1991年 | 442篇 |
1990年 | 393篇 |
1989年 | 335篇 |
1988年 | 314篇 |
1987年 | 243篇 |
1986年 | 227篇 |
1985年 | 912篇 |
1984年 | 1111篇 |
1983年 | 893篇 |
1982年 | 994篇 |
1981年 | 932篇 |
1980年 | 700篇 |
1979年 | 647篇 |
1978年 | 457篇 |
1977年 | 364篇 |
1976年 | 414篇 |
1975年 | 317篇 |
1973年 | 199篇 |
Objective
The study objective was to screen patients with acute type A aortic dissection for anatomic feasibility of ascending aortic endovascular treatment with a valve-carrying conduit.Methods
High-quality computed tomography scans of 167 patients were available for screening. Aortic dimensions were measured using multiplanar reconstruction in the plane perpendicular to the manually corrected aortic center line. The simulated stent-graft 10-mm–long landing zones were measured starting at the sinotubular junction (proximal landing zone) and ending at the brachiocephalic trunk (distal landing zone). Exclusion criterion was an entry within the aortic root or the landing zone.Results
In 113 patients (68%), the entry was in a coverable zone in the ascending aorta with sufficient proximal and distal landing zone or in more distal aortic segments. In these patients, the median distance between the proximal and distal landing zone was 89.1 (first quartile: 80.0 mm; third quartile: 101.2 mm) and the median diameter difference was 5.0 mm (2.0; 10.1) (12.3 [4.9; 23.0] %). The diameter difference was less than 2 mm in 32 patients (28%), between 6 mm and 10 mm in 20 patients (18%), between 10 mm and 14 mm in 11 patients (10%), and 14 mm or greater in 10 patients (9%).Conclusions
Two thirds of all patients who present with type A dissections are potential candidates for treatment with endovascular valve–carrying conduits, but most patients would require tapered stent-grafts. 相似文献Materials and Methods: Five individuals affected with CDPD from three unrelated Chilean families were clinically and genetically examined. To evaluate a putative founder mutation 7 SNPs were analyzed in the three families, an Argentinian patient (carrier of the same mutation previously reported) and 87 Chilean controls.
Results: The ophthalmic symptoms in the five patients were bilateral and symmetric, starting before one year of age, and visual acuity varied from 0.1 to 0.3. In all cases, hearing loss began over 8 years old. The sequence of the 19 exons of SLC4A11 gene of all the affected patients exhibited homozygous eight nucleotide sequence duplication (c.2233_2240dup TATGACAC, p.(Ile748Metfs*5)) at the end of exon 16. All the affected patients of the three families were homozygous for a haplotype composed of five SNPs and covering 4,1 Mb. The same haplotype was present in one allele of the heterozygous Argentinean patient and has a frequency of 2.76% in Chilean population.
Conclusions: The five CDPD patients were homozygous for the same mutation in the SLC4A11 gene. Haplotype analysis of all the affected, including the case reported from Argentina was in accordance with a founder mutation. 相似文献
Coumadin (R/S-warfarin) metabolism plays a critical role in patient response to anticoagulant therapy. Several cytochrome P450s oxidize warfarin into R/S-6-, 7-, 8-, 10, and 4′-hydroxywarfarin that can undergo subsequent glucuronidation by UDP-glucuronosyltransferases (UGTs); however, current studies on recombinant UGTs cannot be adequately extrapolated to microsomal glucuronidation capacities for the liver.
Herein, we estimated the capacity of the average human liver to glucuronidate hydroxywarfarin and identified UGTs responsible for those metabolic reactions through inhibitor phenotyping. There was no observable activity toward R/S-warfarin, R/S-10-hydroxywarfarin or R/S-4′-hydroxywarfarin.
The observed metabolic efficiencies (Vmax/Km) toward R/S-6-, 7-, and especially 8-hydroxywarfarin indicated a high glucuronidation capacity to metabolize these compounds.
UGTs demonstrated strong regioselectivity toward the hydroxywarfarins. UGT1A6 and UGT1A1 played a major role in R/S-6- and 7-hydroxywarfarin glucuronidation, respectively, whereas UGT1A9 accounted for almost all of the generation of the R/S-8-hydroxywarfarin glucuronide.
In summary, these studies expanded insights to glucuronidation of hydroxywarfarins by pooled human liver microsomes, novel roles for UGT1A6 and 1A9, and the overall degree of regioselectivity for the UGT reactions.